The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
It's from the Medica tradefair in Germany. Managed to source it . Unfortunately all the Medusa guys had gone home by Thurs afternoon but there was a load of brochures that they left.
There has been a similar discussion regarding this before. The only option is to put down antibodies on the initial form, then if / when it needs to be reviewed manually then they can clarify, but pretty standard practice.
Wouldnt even bother reading that! Says it was posted by SimplyWallSt. Thats almost as bad as the MotleyFool
Ticino, choose not to believe it, it won't be anyone's loss. But why don't you just pick up the phone and find out for yourself! There's been a few of us that have spoken to Medusa now and for a lengthy convo each time.
This week some of the team have been over in Germany at the conference where I managed to source that brochure today. So might be harder to get in contact with them, but when you do it's very clear they're frustrated with delays, excited for what they have coming and a real buzz about it all.
At the end of the day, there's some good posters on here who are completely legit and deserve more respect for the info they share. They put in the effort and opinions like that are just rude and lazy.
Its 100% legit @Zoom0001, from the Medica stand in Germany right now.
All I will say is, pick up the phone to Medusa and you'll be surprised at how open they are regarding Affidx. Very shrewd at what they do and theres been so much going on in the background, a lot of orders waiting on that HUA ;)
For reference to Medusa changing to a manufacturer earlier this year "Medusa 19 changed its SIC Code (Code for the main activity of the company) and is now officially a manufacturer...":
https://twitter.com/boy_cellar/status/1393550775503183876
Timster, can 100% guarantee Medusa are manufacturing and will be an absolute beast at that! They changed on the Gov document to a manufacturer .
Watch the video from a year ago and listen to them say "we're up to a supply chain of 100m a month.. can scale this to significant volumes”. Now given that volume and that it was last year, everything will be ironed out by now and ready to roll.
https://alderleyanalytical.com/good-luck-medusa-19/
They have also stated they guarantee 2m tests in stock incase demand increases to meet orders (once again can scale).
"We have received significant purchase orders for manufacturing batches from Vatic and Avacta, in advance of completion of technical transfer of their products, and we are putting in place the required component stock to allow us to seamlessly move into manufacturing in due course. The transfer of these antigen tests is timely given the move towards private-sector testing in the UK, the transition to cost-effective lateral flow testing from PCR testing for travel as well as the increased focus on antigen testing starting to emerge in the United States."
"Our overall capacity is currently over 150 million tests in laminated card format and up to 85 million foiled devices and we have the space to bring in additional automation taking our secondary production capacity to over 140 million foiled devices. This dual-site capability provides significant flexibility as we can manufacture the same products on both sites and offers our customers assurance from a risk management perspective in the event that one site is unable to operate for a period (e.g. due to a COVID-19 outbreak)."
So significant orders from Avacta, that would therefore mean that we have a large order book and therefore means that Calibre have been selling everything they get from GAD. Very bullish that imo.
Oh yeah and ABDX is just the small manufacturer compared to Medusa. Are the rumours true and we hear from Medusa this week? Hopefully they like to spice things up with an intraday.
@MrDribbles, I first bought Orph around 6p, and personally see it as a much better investment at 19p than it was when I bought a couple years ago. Im in a couple other shares that have suffered with Government delays and its a painful process, however after todays talk its very clear that everything is going to go ahead, absolutely no doubts about that, and the market is just getting bigger.
I went to the London Investor Show a couple weeks ago and one talker said to ignore all the noise between A-Z, as too many people are fixated on the share price and not the company. They'll lose faith and end up selling to rainbow chase elsewhere, whereas this is the sort of company that you want to be invested in, high in demand, growing each year, sector growth etc, and in the end you'll always be rewarded.
A few points I've put in a Twitter thread. Have to say that was a brilliant talk by Bruno and I've come out of that the most positive as I've ever been with Orph. Its very clear that everything is going ahead and literally no concerns from MHRA at all and theyve been outstanding throughout the whole process being very supportive with us. There are a lot of companies from small to large biotechs in discussions with us and a number of those are very advanced. These are ranging from vaccines to anti virals. Both will happen and the delays are out of Cathals hands, its a very complex environment with so many parties involved so takes time to review the paper.
I missed the first bit of the talk as well so probably more to the talk, but just a few snippets before the video is available to watch back.
I WILL buy more tomorrow. Very very confident here
https://twitter.com/downunderfutbol/status/1460647147276320773
Believe you've posted the wrong link Timster! You linked the ABDX Twitter post rather than the Bmj COVID-19 rapid research paper
Very misleading headline by the Mail.
Read down the article and see the bullet points which is what we were expecting anyway with them ending free testing and moving to the private sector. Makes sense as higher prices and they can make money back via tax:
End free Covid tests and instead allow private companies to charge for lateral flow and PCR tests;
Shut down the national 'Test and Trace' system, which identifies those who may have been exposed to the virus;
Focus the fight against Covid on tackling local outbreaks and protecting 'highest risk settings', such as care homes
AgentB, do you realise the minimum market cap for the small cap MSCI index is 200m MC.
Right now, Avacta is at 272m MC. Well above the minimum requirement. The requirements arent just based on MC, and there are other factors, but I would say its extremely unlikely that would fall out of this. Will be announced 10pm UK time tonight anyway.
Elrico, have you thought about doing an audio recording the presentation from Cathal and uploading it towards the end of the week (for a fee / donation of course). I think theres a lot of people here who would love to attend but can't make it due to being hard to get to and back being a midweek night.
I would like to know if he is waiting on full approval of the original strain so they can start anti viral work at the start of next year - and when that happens does that open the door to a higher valuation for DIM given we would then have more covid data?
@NDN71 it very much is a separate study:
AVCT’s CV used 200 samples: 98 positive samples (96/98) and 102 negative samples (101/102).
This study used 250 samples: 100 positive samples (98/100) and 150 negative samples (150/150).
From Myles
Jog on Greedo76.
Ethical Tout is a breath of fresh air compared to the absolute repetitive drivel that Bishop posts every couple of hours... Very well balanced views on Avacta, not afraid to say where theyve gone wrong but to also highlight what the market opportunities are that many arent aware of and why they are almost perfectly placed to take advantage.
Its very clear he believes APAC is a big and relatively easy market for us, another tweet this morn regarding it:
https://twitter.com/TheEthicalTout/status/1453290322335879172
So looks like Medusa can self declare from 25th Oct... Time for them to ramp up that marketing campaign:
Self-declaration
Providers must also complete a declaration that their tests meet all of these standards. This will be made available the week commencing 25 October 2021. As well as declaring that they meet the minimum standards at the start of the service, they must maintain these standards from 12 November 2021, and implement and maintain any revisions to the standards, within a reasonable time period.
This self-declaration must only be completed by front-end providers who will be directly selling day 2 lateral flow tests for mandatory coronavirus (COVID-19) testing for international arrivals who are eligible to follow the rules for fully vaccinated individuals.
The providers completing the self-declaration will self-declare on behalf of themselves and all of the organisations they’re working with to provide these tests. They will need to list all organisations that they will be working with (whether by subcontract or otherwise) in order to carry out this service.
If there is a change to any information submitted in their self-declaration, the provider will need to notify the Department of Health and Social Care (DHSC) of the nature of the new arrangement.
200k shares bought at 122.5, well over the premium which was 118. Some confidence there going into tomorrow.
@digitalman Calibre / Bioserv are the same Company:
https://bioservuk.com/product/avacta-affidx-sars-cov-2-antigen-lateral-flow-test/